SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
IN PARTNERSHIP WITH ECLIPSEBIO
Webinar: The Future of mRNA Medicine: How Advanced Data Empowers Cures
This discussion focuses on how sequencing-based insights can power AI-driven design and data-driven validation, helping to develop safe and effective drugs for treating and preventing disease.
October 22, 2025
 · 
1 min read
 · 
BioSpace Insights
Hands reach out to each other. Handshake. Halftone retro hands. Body parts cut out of newspaper. Hands tied with thread. Shaking hands. Make a deal. Successful agreement. Modern collage
Mergers & acquisitions
Ipsen Puts Up $1.6B To Absorb ImCheck for Mid-Stage Leukemia Antibody
The deal focuses on ICT01, a monoclonal antibody being tested in acute myeloid leukemia. ImCheck is also developing assets in infectious disease and other oncology indications.
October 22, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Exclusive magazine collage image of hand hold flag yuan euro dollar currency trade war bank usa europe china economy embargo.
Drug pricing
Trump To Target Trading Partners With Drug Pricing Probe: Report
While the threat of tariffs dies down for the pharma industry, President Donald Trump is reportedly weighing a new investigation that could result in import taxes against U.S. trading partners that don’t pay enough for drugs.
October 22, 2025
 · 
1 min read
 · 
Annalee Armstrong
Illustration of scales of justice tipping to one side
Job Trends
Most Employers Consider Hiring but Worry About Overqualified Job Candidates: Survey
Seven in 10 U.S. hiring managers say their company usually considers employing overqualified applicants, according to a survey from Express Employment Professionals and The Harris Poll. However, 75% of employers believe such hires struggle to stay motivated in lower-level roles.
October 22, 2025
 · 
3 min read
 · 
Angela Gabriel
Museum island on Spree river and Alexanderplatz TV tower in center of Berlin, Germany
Cancer
ADC, Bispecifics and Kinase Blockers Steal the Spotlight at ESMO 2025 in Berlin
Pfizer, Merck, AstraZeneca and Bristol Myers Squibb were among the many biopharmas showing off novel cancer modalities at ESMO, with antibody-drug conjugates, bispecific antibodies and kinase inhibitors demonstrating encouraging efficacy and safety for various cancers.
October 22, 2025
 · 
4 min read
 · 
Tristan Manalac
Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.
Obesity
Terns Turns Away From Obesity Pill After ‘Uncompetitive’ Phase II Profile
Two patients experienced grade 3 liver enzyme elevations that were deemed related to Terns’ investigational obesity pill TERN-601.
October 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Cambridge, Massachusetts, USA - 30 July 2024. Takeda Pharmaceutical Company logo on office building.Biotech industry
Antibody-drug conjugate (ADC)
Takeda Bets up to $11.4B for Up To Three Innovent Cancer Assets
For $1.2 billion upfront and up to $10.2 billion in milestones, Takeda will gain access to a bispecific antibody fusion protein targeting both the PD-1 and IL-2 pathways, among other assets.
October 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Human head with puzzle pieces and doodles vector illustration. Human brain lacking a piece of puzzle. Concept of brain function, memory loss, disorder, dementia. Abstract human head profile
Neuropsychiatric disorders
Alector Scraps Dementia Drug After Phase III Flop, Lays Off 49% of Staff
This represents Alector’s second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in Alzheimer’s last November. On latozinemab for frontotemporal dementia, Alector was working with GSK, which fronted $700 million in 2021 to collaborate on two programs.
October 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Gold bull and bear on each side of a wooden seesaw in gradient blue background. Illustration of the concept of bullish and bearish market, change of stock prices and risk of investment
Venture capital
Biotech Markets Turn Positive but Experts Say Don’t Call It a Comeback—Yet
M&A is back, the S&P XBI is rising again, a biotech pulled off an IPO and positive data is pulling in investors again. This may just be the industry’s new normal.
October 22, 2025
 · 
7 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS